Perrigo (NYSE:PRGO) Releases FY 2026 Earnings Guidance

Perrigo (NYSE:PRGO) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 2.250-2.550 for the period, compared to the consensus EPS estimate of 2.700. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.2 billion.

Perrigo Stock Performance

Shares of NYSE PRGO opened at $13.23 on Friday. Perrigo has a 1 year low of $12.17 and a 1 year high of $30.93. The firm has a market cap of $1.82 billion, a P/E ratio of -1.29, a PEG ratio of 1.27 and a beta of 0.39. The stock has a fifty day moving average price of $14.41 and a two-hundred day moving average price of $17.49. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.44 and a current ratio of 2.51.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing the consensus estimate of $0.80 by ($0.03). Perrigo had a negative net margin of 33.51% and a positive return on equity of 8.62%. The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the company earned $0.93 EPS. The company’s quarterly revenue was down 2.5% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Research analysts forecast that Perrigo will post 2.56 EPS for the current fiscal year.

Perrigo Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 24th. Shareholders of record on Monday, March 2nd will be issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 8.8%. The ex-dividend date of this dividend is Monday, March 2nd. Perrigo’s dividend payout ratio is presently -11.28%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PRGO. Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a research note on Thursday. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a research report on Friday, February 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Canaccord Genuity Group reduced their price objective on Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Friday. Finally, JPMorgan Chase & Co. cut their target price on Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $19.33.

Perrigo News Summary

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Analyst support remains: Canaccord trimmed its price target from $20 to $17 but kept a “buy” rating, signaling some analysts still see upside versus the current share level. Canaccord price target note (Benzinga)
• Positive Sentiment: Company execution items: Perrigo says FY2025 adjusted EPS landed at the midpoint of its updated outlook, advanced a “3‑S” commercial plan, gained share in OTC/store‑brand categories, and launched operational savings expected to deliver $80–$100M pre‑tax annualized — all items that support longer‑term margin recovery. PR Newswire: FY2025 results & initiatives
• Neutral Sentiment: Analyst/investor materials available — full earnings call transcript and slide deck were published for investors who want details on segment reporting changes and management commentary. Reviewing these can help assess whether guidance and the formula exposure are temporary. Earnings call transcript/highlights (Yahoo)
• Negative Sentiment: Q4 miss on EPS: Perrigo reported $0.77 EPS vs. consensus ~$0.80 and EPS is down year‑over‑year (prior $0.93), which eroded near‑term investor confidence despite a slight revenue beat. Zacks: Q4 earnings miss & analysis
• Negative Sentiment: Weaker FY2026 outlook: Management set FY2026 EPS guidance at $2.25–$2.55 (below the ~$2.70 consensus) and reiterated revenue guidance below/at consensus, explicitly calling out Infant Formula as a drag and introducing a ‘CORE’ view that excludes formula/divestitures — the guidance shortfall and exposed category risk are the main reasons the stock is down. Zacks: weak 2026 guidance & formula headwinds

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fuller & Thaler Asset Management Inc. lifted its position in Perrigo by 291.9% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock worth $108,921,000 after buying an additional 5,828,076 shares in the last quarter. Invesco Ltd. increased its stake in shares of Perrigo by 134.2% in the fourth quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock worth $63,230,000 after acquiring an additional 2,602,724 shares during the last quarter. ION Fund Management Ltd acquired a new position in shares of Perrigo in the fourth quarter worth $24,499,000. Ion Asset Management Ltd. raised its holdings in shares of Perrigo by 34.7% during the second quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock worth $102,007,000 after acquiring an additional 983,727 shares in the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in Perrigo during the fourth quarter valued at $9,165,000. 95.91% of the stock is owned by hedge funds and other institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.